A, cell cycle arrest in GBM neurospheres with vismodegib treatment <i>in vitro</i> a) A49910, b), B0027, c) B0043, d) B0051 and e) M45481.

<p><b>B</b>, Number of apoptotic cells (annexin V positive) in GBM neurospheres treated either with DMSO or with 50 μM vismodegib.</p

Heat map of correlation matrix for the expression of 11 canonical Hh-pathway component genes in TCGA-GBM (N = 149, significant cut-off |r|>0.17, MTC with FDR 0.1).

<p>Heat map of correlation matrix for the expression of 11 canonical Hh-pathway component genes in TCGA-GBM (N = 149, significant cut-off |r|>0.17, MTC with FDR 0.1).</p

Log scale distribution of GLI1 mRNA expression in a) already published MB cases, along with 1 new case of MB from our repository b) distribution of GLI1 mRNA expression (RNA-Seq data) of the TCGA-GBM sub-cohort (N = 149), c) distribution of GLI1 mRNA expression in NIBMG-GBM cases (N = 19), d) distribution of GLI1 mRNA expression in GBM patient-derived early passage neurospheres (N = 6) and e) comparison of median GLI1 mRNA expression levels of high-Hh-MB (N = 13), low-Hh-MB (N-44), NIBMG-GBM (N = 19) and GBM patient-derived neurospheres (N = 6).

<p>Log scale distribution of GLI1 mRNA expression in a) already published MB cases, along with 1 new case of MB from our repository b) distribution of GLI1 mRNA expression (RNA-Seq data) of the TCGA-GBM sub-cohort (N = 149), c) distribution of GLI1 mRNA expression in NIBMG-GBM cases (N = 19), d) distribution of GLI1 mRNA expression in GBM patient-derived early passage neurospheres (N = 6) and e) comparison of median GLI1 mRNA expression levels of high-Hh-MB (N = 13), low-Hh-MB (N-44), NIBMG-GBM (N = 19) and GBM patient-derived neurospheres (N = 6).</p